Since we found that most COX-2 mediated mechanisms in breast cancer progression result from EP4 activation, we suggest that TNBCs will respond to EP4 antagonist (EP4A) therapy and miR655 could be used as a plasma biomarker for therapeutic monitoring in TNBC patients. This evidence concerns the gene PTGER4 and breast carcinoma.